AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26781431 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density by dual-energy X-ray absorptiometry (DXA) at femoral neck
Number of subjects: 89
Study 26781431 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density by dual-energy X-ray absorptiometry (DXA) at lumbar spine
Number of subjects: 89
Study 26781431 — intervention group
Group type: COMPARATOR
Intervention: Speed-of-sound (SOS) ultrasonography at forearm (FA)
Number of subjects: 89
Study 26781548 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemia (3.5 h clamp period)
Number of subjects: 24
Study 26781724 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) 1.0 mg plus Tenofovir (TDF) 300 mg combination therapy for 48 weeks
Number of subjects: 64
Study 26781785 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound7 (US7)
Number of subjects: 82
Study 26781785 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound12 (US12)
Number of subjects: 82
Study 26781785 — intervention group
Group type: COMPARATOR
Intervention: Infliximab treatment
Number of subjects: 82
Study 26781785 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS28
Number of subjects: 82
Study 26781785 — intervention group
Group type: EXPERIMENTAL
Intervention: GS + PD
Number of subjects: 82
Study 26781817 — intervention group
Group type: EXPERIMENTAL
Intervention: High BCAA content diet (14.0±0.6 g valine, 13.8±0.5 g isoleucine, 27.1±1.0 g leucine)
Number of subjects: 5
Study 26781817 — intervention group
Group type: COMPARATOR
Intervention: Low BCAA content diet (1.5±0.1 g valine, 4.5±0.9 g isoleucine, 2.1±0.2 g leucine)
Number of subjects: 5
Study 26782632 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin-resistant Escherichia coli (CipREc) isolates
Number of subjects: 227
Study 26782632 — intervention group
Group type: EXPERIMENTAL
Intervention: O25b-ST131 lineage CipREc isolates
Number of subjects: 227
Study 26782796 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursery songs intervention; details on dosage and duration not specified.
Number of subjects: 0
Study 26782796 — intervention group
Group type: COMPARATOR
Intervention: Control group; details on intervention not specified.
Number of subjects: 0
Study 26782971 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC 125 μg once daily
Number of subjects: 153
Study 26783523 — intervention group
Group type: EXPERIMENTAL
Intervention: Atlas vertebrae realignment intervention
Number of subjects: 11
Study 26783591 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in psychological research
Number of subjects: 0
Study 26784028 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic thyroid hormone (levothyroxine)
Number of subjects: 10
Study 26784028 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical hyperthyroid state (after treatment)
Number of subjects: 10
Study 26784138 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin 50 mg bid and escalating doses of bortezomib (1 to 1.3 mg/m2)
Number of subjects: 0
Study 26784138 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin and bortezomib following chemotherapy with mitoxantrone, etoposide, cytarabine (MEC)
Number of subjects: 0
Study 26784704 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine maintenance therapy (dosages ranging from 50 to 900 mg, median dosage of 500 mg)
Number of subjects: 131
Study 26784704 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 131
Study 26784946 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chemotherapy
Number of subjects: 68
Study 26785287 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-486 (oral azacitidine) maintenance therapy (300 mg/day for 14 days of 28-day treatment cycles)
Number of subjects: 0
Study 26785287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26785742 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital quantification of B lymphocytes using anti-CD20 antibodies and image analysis.
Number of subjects: 62
Study 26785742 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital quantification of T lymphocytes using anti-CD3 antibodies and image analysis.
Number of subjects: 62
Study 26785742 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital method for quantifying B cells.
Number of subjects: 62
Study 26785742 — intervention group
Group type: EXPERIMENTAL
Intervention: B-cell proportion in biopsies with Chisholm grades I-II vs III-IV.
Number of subjects: 62
Study 26785742 — intervention group
Group type: EXPERIMENTAL
Intervention: B-cell proportion across Tarpley's classes.
Number of subjects: 62
Study 26785742 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of B-cell proportion with clinical and biological activity markers.
Number of subjects: 62
Study 26785798 — intervention group
Group type: EXPERIMENTAL
Intervention: Health anxiety (hypochondriasis)
Number of subjects: 194
Study 26786685 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection (EMR) for SSA/Ps
Number of subjects: 2000
Study 26786685 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic mucosal resection (EMR) for adenomas
Number of subjects: 2000
Study 26787251 — intervention group
Group type: EXPERIMENTAL
Intervention: ERSIAS anaesthesia protocol
Number of subjects: 24
Study 26787251 — intervention group
Group type: COMPARATOR
Intervention: Standard anaesthetic care (Control)
Number of subjects: 24
Study 26787381 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive developmental quotients in children with rapidly progressing MPS IIIA
Number of subjects: 25
Study 26787381 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive developmental quotients in children with slowly progressing MPS IIIA
Number of subjects: 25
Study 26787381 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver and spleen volumes
Number of subjects: 25
Study 26787381 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid and urine heparin sulfate levels
Number of subjects: 25
Study 26787381 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental quotient and cortical gray matter volume
Number of subjects: 25
Study 26787437 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular endocardial pacing (LVEP)
Number of subjects: 138
Study 26787795 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative transfusion of packed red blood cells (pRBC)
Number of subjects: 5803
Study 26787832 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hemagglutinin-based vaccine
Number of subjects: 0
Study 26788114 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain group (n=40)
Number of subjects: 80
Study 26788114 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=40)
Number of subjects: 80
Study 26788345 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GEn) 600 mg
Number of subjects: 671
Study 26788345 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GEn) 1200 mg
Number of subjects: 671
Study 26788345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 671
Study 26790007 — intervention group
Group type: EXPERIMENTAL
Intervention: Early loading of splinted OsseoSpeed(™) TX implants
Number of subjects: 45
Study 26790369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo costimulatory blockade with belatacept during mixed lymphocyte culture
Number of subjects: 0
Study 26790480 — intervention group
Group type: COMPARATOR
Intervention: AAV2 neutralizing antibodies (NAbs)
Number of subjects: 42
Study 26790480 — intervention group
Group type: COMPARATOR
Intervention: AAV8 neutralizing antibodies (NAbs)
Number of subjects: 42
Study 26790480 — intervention group
Group type: COMPARATOR
Intervention: AAV9 neutralizing antibodies (NAbs)
Number of subjects: 42
Study 26790480 — intervention group
Group type: COMPARATOR
Intervention: NAbs in patients older than 18 years or those who had received solid organ transplantation
Number of subjects: 42
Study 26790480 — intervention group
Group type: COMPARATOR
Intervention: mut(0) patients who had not been transplanted
Number of subjects: 42
Study 26791079 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes camp attendance
Number of subjects: 32
Study 26791256 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncogramme
Number of subjects: 19
Study 26791256 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncogramme (supplementary analysis)
Number of subjects: 19
Study 26792544 — intervention group
Group type: EXPERIMENTAL
Intervention: F/B-EVAR
Number of subjects: 354
Study 26792613 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical shoes
Number of subjects: 42
Study 26792613 — intervention group
Group type: COMPARATOR
Intervention: Preoperative condition (control run)
Number of subjects: 42
Study 26793344 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided biopsy
Number of subjects: 132
Study 26793344 — intervention group
Group type: COMPARATOR
Intervention: Bronchoscopy
Number of subjects: 132
Study 26793344 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathology
Number of subjects: 132
Study 26793344 — intervention group
Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 132
Study 26793344 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR mutation testing
Number of subjects: 132
Study 26793344 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications
Number of subjects: 132
Study 26793618 — intervention group
Group type: EXPERIMENTAL
Intervention: PC + D (Pemetrexed at 500 mg/m² and Cisplatin at 75 mg/m² IV every 3 weeks, Dalotuzumab at 10 mg/kg IV weekly on days 1, 8, and 15 of every 3-week cycle)
Number of subjects: 26
Study 26793618 — intervention group
Group type: COMPARATOR
Intervention: PC (Pemetrexed at 500 mg/m² and Cisplatin at 75 mg/m² IV every 3 weeks)
Number of subjects: 26
Study 26793618 — intervention group
Group type: EXPERIMENTAL
Intervention: PC + D
Number of subjects: 26
Study 26793618 — intervention group
Group type: COMPARATOR
Intervention: PC
Number of subjects: 26
Study 26793976 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral ART daily for 4 weeks
Number of subjects: 23
Study 26793976 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg oral ART daily for 4 weeks
Number of subjects: 23
Study 26793976 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg oral ART daily for 4 weeks
Number of subjects: 23
Study 26793974 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg/day (phase II)
Number of subjects: 47
Study 26793974 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (multiple doses in phase I)
Number of subjects: 47
Study 26794905 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily dosing of celgosivir starting on day 0
Number of subjects: 0
Study 26794905 — intervention group
Group type: COMPARATOR
Intervention: Twice daily dosing of celgosivir starting on day 3
Number of subjects: 0
Study 26794905 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-times daily treatment of celgosivir
Number of subjects: 0
Study 26795217 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vitamin A concentration
Number of subjects: 189
Study 26795217 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vitamin C concentration
Number of subjects: 189
Study 26795217 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vitamin E concentration
Number of subjects: 189
Study 26795447 — intervention group
Group type: EXPERIMENTAL
Intervention: Web- and mobile-based The-Optimal-Lymph-Flow intervention
Number of subjects: 120
Study 26795447 — intervention group
Group type: COMPARATOR
Intervention: Web- and mobile-based Arm Precaution program
Number of subjects: 120
Study 26795844 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg/kg palonosetron
Number of subjects: 502
Study 26795844 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg/kg palonosetron
Number of subjects: 502
Study 26795844 — intervention group
Group type: COMPARATOR
Intervention: 3×150 μg/kg ondansetron
Number of subjects: 502
Study 26796197 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetrical concentric pmVSD occluder
Number of subjects: 337
Study 26796197 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetrical concentric pmVSD occluder
Number of subjects: 337
Study 26796197 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter closure of pmVSDs using modified double-disk occluders
Number of subjects: 337
Study 26796290 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic curvature measurement over the juxtarenal aortic neck, aneurysm sac, and terminal aorta.
Number of subjects: 143
Study 26796290 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic neck calcification measurement.
Number of subjects: 143
Study 26796290 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic neck angulation measurement.
Number of subjects: 143
Study 26796390 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-stage percutaneous coronary intervention (1S-PCI)
Number of subjects: 584
Study 26796390 — intervention group
Group type: COMPARATOR
Intervention: multistage percutaneous coronary intervention (MS-PCI)
Number of subjects: 584
Study 26796402 — intervention group
Group type: EXPERIMENTAL
Intervention: P-Selectin Antagonist Inclacumab
Number of subjects: 0
Study 26796402 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26796806 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal mammary sentinel lymph node biopsy (IM-SLNB)
Number of subjects: 349
Study 26796810 — intervention group
Group type: EXPERIMENTAL
Intervention: Single subcutaneous injection of 100 μg/kg pegylated filgrastim
Number of subjects: 53
Study 26796810 — intervention group
Group type: COMPARATOR
Intervention: Daily subcutaneous injections of 5 μg/kg filgrastim
Number of subjects: 53
Study 26796885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Number of subjects: 82
Study 26797207 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral co-formulated tenofovir/emtricitabine (PrEP)
Number of subjects: 0
Study 26797214 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz-based cART
Number of subjects: 30
Study 26797214 — intervention group
Group type: COMPARATOR
Intervention: Atazanavir/Ritonavir-based cART
Number of subjects: 30
Study 26797214 — intervention group
Group type: COMPARATOR
Intervention: No cART
Number of subjects: 30
Study 26797234 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident diabetes complications (any one of the seven complications: stroke, heart failure, myocardial infarction, ischemic heart disease, renal failure, blindness, and amputation)
Number of subjects: 0
Study 26797234 — intervention group
Group type: EXPERIMENTAL
Intervention: Amputation
Number of subjects: 0
Study 26797234 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke
Number of subjects: 0
Study 26797234 — intervention group
Group type: EXPERIMENTAL
Intervention: Blindness
Number of subjects: 0
Study 26797234 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal failure
Number of subjects: 0
Study 26797234 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 0
Study 26797234 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial infarction
Number of subjects: 0
Study 26797234 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic heart disease
Number of subjects: 0
Study 26797234 — intervention group
Group type: EXPERIMENTAL
Intervention: Elapsed time
Number of subjects: 0
Study 26797464 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day interactive educational seminar on evidence-based guidelines about managing RTIs
Number of subjects: 203
Study 26797464 — intervention group
Group type: COMPARATOR
Intervention: Control group (no seminar)
Number of subjects: 203
Study 26797464 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention modalities (seminar and problem-solving training)
Number of subjects: 203
Study 26797802 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (300-400 mg daily for ≥ 1 month)
Number of subjects: 27
Study 26797802 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib therapy
Number of subjects: 27
Study 26798624 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (12 weeks course)
Number of subjects: 32
Study 26798647 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Message Service (SMS) intervention
Number of subjects: 0
Study 26798647 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical practice (control)
Number of subjects: 0
Study 26798650 — intervention group
Group type: EXPERIMENTAL
Intervention: DCM-AGT
Number of subjects: 10
Study 26798650 — intervention group
Group type: EXPERIMENTAL
Intervention: DCM-NGT
Number of subjects: 10
Study 26798650 — intervention group
Group type: EXPERIMENTAL
Intervention: N-AGT
Number of subjects: 10
Study 26798650 — intervention group
Group type: EXPERIMENTAL
Intervention: DCM patients
Number of subjects: 10
Study 26798977 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid implant
Number of subjects: 0
Study 26798977 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy
Number of subjects: 0
Study 26799743 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (3 x 2.5 g/d) and metformin (2 x 250 mg/d) for 16 weeks
Number of subjects: 5
Study 26800061 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Number of subjects: 7170
Study 26800632 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological attribution and emotional awareness and expression therapy
Number of subjects: 72
Study 26800789 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART Pathway ADP implementation
Number of subjects: 10000
Study 26800997 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 μg of ramosetron for 4 weeks, continued for another 48 weeks for responders
Number of subjects: 151
Study 26800997 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg of ramosetron for 48 weeks for non-responders
Number of subjects: 151
Study 26801409 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Cancer Risk Test (LCRT), a 15 gene test measured in normal bronchial epithelial cells (NBEC)
Number of subjects: 403
Study 26801409 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoscopic brushing for NBEC sample collection
Number of subjects: 403
Study 26801409 — intervention group
Group type: EXPERIMENTAL
Intervention: Establishment of an NBEC and matched peripheral blood bio-specimen repository
Number of subjects: 403
Study 26801909 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 32
Study 26801909 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 32
Study 26801909 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin combination therapy (ACT)
Number of subjects: 32
Study 26801983 — intervention group
Group type: EXPERIMENTAL
Intervention: Space GlucoseControl system (SGC) with enhanced Model Predictive Control (eMPC) algorithm
Number of subjects: 508
Study 26802021 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 755
Study 26802181 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging of 32 joints (wrists, metacarpophalangeal joints, proximal interphalangeal joints, metatarsophalangeal joints)
Number of subjects: 136
Study 26802181 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound abnormalities (GS ≥2, PD ≥1 or erosion ≥1)
Number of subjects: 136
Study 26802181 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Doppler signal
Number of subjects: 136
Study 26803277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor 50 mg (if bodyweight <14 kg) or 75 mg (if bodyweight ≥14 kg) every 12 h for 4 days (part A) and then for 24 weeks (part B)
Number of subjects: 43
Study 26803277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor 50 mg or 75 mg
Number of subjects: 43
Study 26803420 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral transcatheter aortic valve replacement (TF-TAVR)
Number of subjects: 1063
Study 26803446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir (90 mg ledipasvir and 400 mg sofosbuvir orally once per day for 12 weeks)
Number of subjects: 41
Study 26803597 — intervention group
Group type: EXPERIMENTAL
Intervention: Low PAMP diet for 7 days
Number of subjects: 24
Study 26803597 — intervention group
Group type: COMPARATOR
Intervention: High PAMP diet after 4 days
Number of subjects: 24
Study 26803597 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh onion meal
Number of subjects: 24
Study 26803597 — intervention group
Group type: COMPARATOR
Intervention: High PAMP equivalent meal
Number of subjects: 24
Study 26803754 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient hepatic elastography (THE) using FibroScan® device
Number of subjects: 50
Study 26803754 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Attenuation Parameter (CAP) software
Number of subjects: 50
Study 26803754 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c and HOMA-IR
Number of subjects: 50
Study 26804761 — intervention group
Group type: EXPERIMENTAL
Intervention: Raindrop Near Vision Inlay
Number of subjects: 373
Study 26805452 — intervention group
Group type: EXPERIMENTAL
Intervention: LA expansion index measurement
Number of subjects: 141
Study 26806010 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (600 mg fixed dose via SC single-use injection device)
Number of subjects: 0
Study 26806010 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (via SC handheld syringe)
Number of subjects: 0
Study 26806010 — intervention group
Group type: COMPARATOR
Intervention: Intravenous trastuzumab
Number of subjects: 0
Study 26806047 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 690
Study 26806047 — intervention group
Group type: COMPARATOR
Intervention: Continued medical management
Number of subjects: 690
Study 26806518 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 2563
Study 26806518 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium monotherapy
Number of subjects: 2563
Study 26806840 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS score ≥ 5
Number of subjects: 77
Study 26806840 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS score ≥ 6
Number of subjects: 77
Study 26806840 — intervention group
Group type: EXPERIMENTAL
Intervention: T-wave alternans (TWA) value
Number of subjects: 77
Study 26808615 — intervention group
Group type: EXPERIMENTAL
Intervention: PRM(fSAD) in participants without airflow obstruction
Number of subjects: 1508
Study 26808615 — intervention group
Group type: EXPERIMENTAL
Intervention: PRM(fSAD) in GOLD 1-4 participants
Number of subjects: 1508